News

. . .

		AboutBoard of directors
Management
Who we are
We build...CompaniesOverview
Internal Portfolio
Companies we’ve helped build
Accelerator
EcosystemsOverview
Innovation Centres
adMare Community
TalentOverview
Executive Institute
BIS Program
Experiential  Learning
adMare Institute
News
Events
CareersCulture
Open positions
Press Room
Contact us
Newsletter

	

			Terms and conditions
    
Français

		
adMare

News
vertical
adMare newsadMare insightsPortfolio companiesadMare AcademyAccelerator companies

						
						February 07 2025
adMare news						
Government of Canada invests $6 million to drive growth in B.C.’s life sciences sector
Read

						
						November 28 2024
adMare news						
adMare BioInnovations Spins Out Analytical Services to Paraza Pharma, Catalyzing Growth and Innovation
Read

						
						October 23 2024
adMare newsPortfolio companies						
Epitopea Closes USD $31 million Pre-Series A Financing
Read

						
						October 02 2024
adMare news						
Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment 
Read

						
						September 20 2024
adMare news						
adMare BioInnovations Appoints Marc Rivière to its Board of Directors 
Read

						
						September 18 2024
adMare newsResident companies						
NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases
Read

						
						September 16 2024
adMare newsPortfolio companies						
Find Therapeutics Announces the Closing of a Convertible Note Financing with Investissement Québec
Read

						
						September 05 2024
adMare news						
Abdera Therapeutics Announces FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma
Read

						
						September 04 2024
adMare news						
PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada
Read

						
						September 03 2024
adMare news						
SOFIAC Canada enables decarbonization of adMare BioInnovations' buildings with a $3.275M investment
Read

						
						August 14 2024
adMare AcademyadMare news						
adMare BioInnovations Opens Applications for the Fall Cohorts of the BioInnovation Scientist Programs  
Read

						
						June 27 2024
adMare news						
adMare BioInnovations Expands with New Wet Laboratory Space in Vancouver 
Read
  1  2  3  4  5  6  7
Newsletter

Stay up to date on the

latest adMare news
Subscribe
Français
Vancouver Innovation Centre2405 Wesbrook Mall

Vancouver, British Columbia, Canada

V6T 1Z3
T. 604.827.1147
Toronto OfficeMaRS Centre, West Tower

661 University Ave., Suite 415

Toronto, Ontario, Canada

M5G 1M1
T. 416.673.8100
Montreal Innovation Centre7171 Frederick-Banting

Montréal, Québec, Canada

H4S 1Z9
T. 514.375.3334
We

	build ...
Companies
Ecosystems
Talent
Who we are
adMare Institute
News
Events
Careers
Newsletter
Contact Us
Press Room
  
adMare

Community
Français
adMare BioInnovations Année all rights reserved - Privacy policy
Website by Riposte
 

                
                    Powered by 
                    
                
            

adMare News

Government of Canada invests $6 million to drive growth in B.C.’s life sciences sector

adMare BioInnovations Spins Out Analytical Services to Paraza Pharma, Catalyzing Growth and Innovation

Epitopea Closes USD $31 million Pre-Series A Financing

Thryv Therapeutics Granted FDA Orphan Drug Designation for LQT-1213 in Long QT Syndrome Treatment

adMare BioInnovations Appoints Marc Rivière to its Board of Directors

NanoVation Therapeutics Announces Multi-Target Partnership with Novo Nordisk to Develop Genetic Medicines Targeting Cardiometabolic and Rare Diseases

Find Therapeutics Announces the Closing of a Convertible Note Financing with Investissement Québec

Abdera Therapeutics Announces FDA Orphan Drug Designation for ABD-147 for the Treatment of Neuroendocrine Carcinoma

PharmaEssentia Announces Licensing Agreement with FORUS Therapeutics to Commercialize BESREMi® (ropeginterferon alfa-2b-njft) in Canada

SOFIAC Canada enables decarbonization of adMare BioInnovations' buildings with a $3.275M investment

adMare BioInnovations Opens Applications for the Fall Cohorts of the BioInnovation Scientist Programs

adMare BioInnovations Expands with New Wet Laboratory Space in Vancouver

Newsletter

Stay up to date on the latest adMare news

Vancouver Innovation Centre

T. 604.827.1147

Toronto Office

T. 416.673.8100

Montreal Innovation Centre

T. 514.375.3334

adMare
News

Stay up to date on the
latest adMare news